TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11429668

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) in combination with clarithromycin for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) used alone or in combination with other antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy with a proton pump inhibitor, clarithromycin and either amoxicillin or a nitroimidazole (tinidazole or metronidazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analogous regimens with RBC in place of proton pump inhibitors
Number of subjects: 0
Study: 9099655

Group type: EXPERIMENTAL
Intervention: Combination diet rich in fruits, vegetables, and low-fat dairy products
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Fruits-and-vegetables diet
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Combination diet (hypertensive subjects)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Combination diet (non-hypertensive subjects)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study: 8058249

Group type: EXPERIMENTAL
Intervention: Universal prenatal screening and selective intrapartum chemoprophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective intrapartum chemoprophylaxis based on clinical risk factors
Number of subjects: 0
Study: 2854762

Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) infusion (5 mg bolus + 2.1 mg/h for 7 h)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily for 6 weeks)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) infusion after tamoxifen administration
Number of subjects: 2
Study: 30111294

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.05 mg/kg (group O1)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg/kg (group O2)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Normal saline (group NS)
Number of subjects: 215
Study: 27625082

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg per day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no olmesartan)
Number of subjects: 116
Study: 25547319

Group type: EXPERIMENTAL
Intervention: Oral health education program (DVD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Newborn nutrition education program (DVD)
Number of subjects: 94
Study: 23915144

Group type: EXPERIMENTAL
Intervention: Baseline physical performance assessment (knee-extension strength, one-legged standing time, walking speed)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: One-legged standing time (sec)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Baseline gray matter volume (voxel-based morphometry)
Number of subjects: 42
Study: 20533438

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 40
Study: 18316463

Group type: EXPERIMENTAL
Intervention: Confidential data monitoring for efficacy
Number of subjects: 0
Study: 15310784

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil
Number of subjects: 448

Group type: COMPARATOR
Intervention: Epirubicin, cyclophosphamide, and granulocyte colony-stimulating factor
Number of subjects: 448
Study: 11575532

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Inhalational anesthesia with isoflurane-nitrous oxide
Number of subjects: 2010
Study: 9576425

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 to 40 mg once daily
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study: 7872726

Group type: EXPERIMENTAL
Intervention: High-dose gestagen treatment (500 mg MPA i.m. twice weekly for three months)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (previous report with abrasio only)
Number of subjects: 82
Study: 3124432

Group type: EXPERIMENTAL
Intervention: Very low dosage of cytosine arabinoside (3mg/m2/twice daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Very low dosage of cytosine arabinoside (3mg/m2/twice daily) with androgens
Number of subjects: 38
Study: 30327912

Group type: EXPERIMENTAL
Intervention: Transection of the hernial sac
Number of subjects: 159

Group type: COMPARATOR
Intervention: Complete dissection of the hernial sac
Number of subjects: 159
Study: 30282393

Group type: COMPARATOR
Intervention: Intraarticular methylprednisolone injection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency ablation
Number of subjects: 30
Study: 26692193

Group type: EXPERIMENTAL
Intervention: ACT‐453859 (400 mg once daily or 100 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Setipiprant (not specified dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT‐453859 and its active metabolite ACT‐463036 (combined concentration)
Number of subjects: 0
Study: 25283715

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 87
Study: 22421745

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg + Atazanavir (ATV) 300 mg twice daily for 4 weeks followed by RAL 800 mg + ATV/ritonavir 300/100 mg once daily for 4 weeks
Number of subjects: 25
Study: 20134307

Group type: EXPERIMENTAL
Intervention: Maximal strength training and conventional rehabilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation only
Number of subjects: 24
Study: 17290336

Group type: EXPERIMENTAL
Intervention: Writing about stressful events (18 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Writing about trivial topics (14 patients)
Number of subjects: 32
Study: 16274368

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (ergocalciferol, initially 10,000 IU weekly then 1,000 IU daily)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study: 11354390

Group type: COMPARATOR
Intervention: 500 mg IR clarithromycin tablets twice daily for 7 days (AECB) or 14 days (AMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg (2 x 500 mg) ER clarithromycin tablets once daily for 7 days (AECB) or 14 days (AMS)
Number of subjects: 0
Study: 9130152

Group type: EXPERIMENTAL
Intervention: Maximum passive inversion range of motion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peak passive resistive torque
Number of subjects: 30
Study: 7708453

Group type: EXPERIMENTAL
Intervention: Saline flush (Group I, n = 68)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Saline flush (Group II, n = 58)
Number of subjects: 126
Study: 3308731

Group type: EXPERIMENTAL
Intervention: Buflomedil, 600 mg daily for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31448953

Group type: EXPERIMENTAL
Intervention: Grand Veggie (vegetarian burger)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Vegetarian labeled burger
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Control group (Big Mac)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Control group (meat-based burger)
Number of subjects: 1126
Study: 30704289

Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping-guided low fluoroscopy PHBP (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional fluoroscopy guided PHBP (group 2)
Number of subjects: 30
Study: 28284473

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP) therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 52
Study: 25218610

Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone prolonged-release (OXN PR)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Oxycodone prolonged-release (OxyPR)
Number of subjects: 128
Study: 22476513

Group type: EXPERIMENTAL
Intervention: QAE-P questionnaire
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Hospital variables (open vs closed ward, disorder-specific organization, number of patients under German Mental Health Act)
Number of subjects: 708
Study: 21099399

Group type: EXPERIMENTAL
Intervention: Nephrology Now e-mail alert service
Number of subjects: 1683

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1683
Study: 20011858

Group type: EXPERIMENTAL
Intervention: Caudal epidural block (ACa)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sciatic and femoral block (IF)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sciatic and saphenous block (IS)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sciatic block and local anesthesia (IL)
Number of subjects: 118

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 118
Study: 16955243

Group type: EXPERIMENTAL
Intervention: Levocetirizine (1.25 mg, 2.5 mg, 5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desloratadine (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15070939

Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 34
Study: 11320783

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9296891

Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry in IDDM patients with peripheral neuropathy
Number of subjects: 30
Study: 8514070

Group type: EXPERIMENTAL
Intervention: 50 mg of lidocaine spray
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 158
Study: 30506630

Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Number of subjects: 275

Group type: COMPARATOR
Intervention: Maintenance immunosuppression
Number of subjects: 275
Study: 29431520

Group type: EXPERIMENTAL
Intervention: trans-resveratrol (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 27611858

Group type: EXPERIMENTAL
Intervention: DAPA (SGLT2 inhibitor)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: DAPA (SGLT2 inhibitor) + PPAR-γ inhibitor GW9662
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 25281710

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 i.v. on day 1 of a 21-day cycle)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 161

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pemetrexed and Gefitinib
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pemetrexed (in patients with EGFR mutation)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Gefitinib (in patients with EGFR mutation)
Number of subjects: 161
Study: 22902793

Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 46
Study: 20375185

Group type: EXPERIMENTAL
Intervention: UNIMMAP supplementation
Number of subjects: 1426

Group type: COMPARATOR
Intervention: Growth-retarded infants
Number of subjects: 1426

Group type: COMPARATOR
Intervention: Offspring of primiparae
Number of subjects: 1426
Study: 18396293

Group type: EXPERIMENTAL
Intervention: Therapeutic strategies targeting endogenous cell sources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current therapeutic strategies in clinical trials
Number of subjects: 0
Study: 16166413

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12472787

Group type: EXPERIMENTAL
Intervention: Progression to microalbuminuria
Number of subjects: 5097

Group type: EXPERIMENTAL
Intervention: Progression from microalbuminuria to macroalbuminuria
Number of subjects: 5097

Group type: EXPERIMENTAL
Intervention: Progression from macroalbuminuria to elevated plasma creatinine or renal replacement therapy (RRT)
Number of subjects: 5097

Group type: EXPERIMENTAL
Intervention: Annual death rate for patients with elevated plasma creatinine or RRT
Number of subjects: 5097

Group type: EXPERIMENTAL
Intervention: Risk of cardiovascular death by nephropathy stage
Number of subjects: 5097

Group type: EXPERIMENTAL
Intervention: Mortality risk comparison
Number of subjects: 5097
Study: 10224345

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g) given intravenously at the induction of anesthesia
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Ceftazidime (2 g) given intravenously at the induction of anesthesia
Number of subjects: 1766
Study: 8903111

Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water ingestion (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water loading (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat ingestion
Number of subjects: 0
Study: 1828962

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alizapride
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tropisetron plus haloperidol
Number of subjects: 32
Study: 6349538

Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) administered intravenously at doses of 1 mg/person/day twice a week or 2 mg/person/day once a week in combination with mitomycin C + 5-FU (MF) or tegafur (FT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control therapy: MF or FT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) as supportive therapy for advanced or recurrent breast cancer
Number of subjects: 0
Study: 31794512

Group type: EXPERIMENTAL
Intervention: St. John's wort (300 mg thrice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31376247

Group type: EXPERIMENTAL
Intervention: Formal statistical help acknowledged (Group I)
Number of subjects: 133

Group type: COMPARATOR
Intervention: No formal statistical help acknowledged (Group II)
Number of subjects: 133
Study: 28682677

Group type: EXPERIMENTAL
Intervention: Polyhexanide/betaine gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 46
Study: 27483647

Group type: EXPERIMENTAL
Intervention: Rectus Sheath Block (RSB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transversus Abdominis Plane Block (TAPB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both RSB and TAPB
Number of subjects: 34
Study: 25079928

Group type: EXPERIMENTAL
Intervention: Continuous ranibizumab (0.5 mg monthly)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Discontinuous ranibizumab (0.5 mg as-needed)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Continuous bevacizumab (1.25 mg monthly)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Discontinuous bevacizumab (1.25 mg as-needed)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Continuous bevacizumab vs Discontinuous bevacizumab
Number of subjects: 610

Group type: COMPARATOR
Intervention: Continuous ranibizumab vs Continuous bevacizumab
Number of subjects: 610
Study: 23099331

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study: 19531929

Group type: EXPERIMENTAL
Intervention: Continuous ART (viral suppression group; VS)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Intermittent ART (drug conservation group; DC)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Continuous ART (VS)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Intermittent ART (DC)
Number of subjects: 214
Study: 17288657

Group type: EXPERIMENTAL
Intervention: Eye gaze angle of 7 degrees
Number of subjects: 53

Group type: COMPARATOR
Intervention: Eye gaze angle of 15 degrees
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Perceived importance of eye contact difference
Number of subjects: 53
Study: 15465622

Group type: EXPERIMENTAL
Intervention: Endocytic dysfunction in early stage AD and DS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-immunofluorescence using Abeta antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-amyloid deposition in neuropathologically confirmed AD
Number of subjects: 0
Study: 11204435

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) 3.0 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osteoprotegerin (OPG)
Number of subjects: 0
Study: 9435420

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-I (IGF-I) at 5 micrograms/kg/h in a continuous s.c. infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 0.03 IU/kg/daily s.c. injection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 8
Study: 7905730

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon gamma (0.1 mg subcutaneously for 10 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon gamma
Number of subjects: 98
Study: 2660252

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study: 31676145

Group type: EXPERIMENTAL
Intervention: ≥60 mL/kg/24 h
Number of subjects: 320

Group type: COMPARATOR
Intervention: <60 mL/kg/24 h
Number of subjects: 320
Study: 31641014

Group type: EXPERIMENTAL
Intervention: Timed 25‐Foot Walk (T25FW)
Number of subjects: 12776

Group type: EXPERIMENTAL
Intervention: 9‐Hole Peg Test (9HPT)
Number of subjects: 12776

Group type: EXPERIMENTAL
Intervention: Low Contrast Letter Acuity (LCLA)
Number of subjects: 12776

Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 12776

Group type: EXPERIMENTAL
Intervention: Multidimensional test battery (including T25FW, 9HPT, LCLA, SDMT)
Number of subjects: 12776

Group type: EXPERIMENTAL
Intervention: Performance measures (individual or multidimensional)
Number of subjects: 12776
Study: 29167536

Group type: EXPERIMENTAL
Intervention: Model 1 (based on respiratory volume, respiratory rate, and age)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Model 2 (incorporating activity categories, heart rate, sex, and BMI)
Number of subjects: 99
Study: 25747391

Group type: EXPERIMENTAL
Intervention: APRN telehealth care coordination intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 148
Study: 23458785

Group type: EXPERIMENTAL
Intervention: Neoprene splint
Number of subjects: 119

Group type: COMPARATOR
Intervention: Thermoplast splint
Number of subjects: 119
Study: 22286628

Group type: EXPERIMENTAL
Intervention: Intermittent sequential compression (ISC) of legs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (without ISC)
Number of subjects: 100
Study: 19224977

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (58% carbohydrate, 27% fat, 15% protein)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Unsaturated-fat diet (48% carbohydrate, 37% fat, 15% protein)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Protein-rich diet (48% carbohydrate, 27% fat, 25% protein)
Number of subjects: 164
Study: 17135809

Group type: EXPERIMENTAL
Intervention: ADL-PI self-rated version
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: ADL-PI informant version
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: MCI ADL questionnaire (informant version)
Number of subjects: 644
Study: 12728216

Group type: COMPARATOR
Intervention: Plain yogurt
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plain kefir
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flavored yogurt
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Flavored kefir
Number of subjects: 15
Study: 10964334

Group type: EXPERIMENTAL
Intervention: Doxil 35 mg/m2 every 3 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Doxil 45 mg/m2 every 3 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Doxil 50 mg/m2 every 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Doxil 60 mg/m2 every 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Doxil 65 mg/m2 every 5 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Doxil 70 mg/m2 every 6 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Doxil (various doses)
Number of subjects: 45
Study: 8795600

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 40
Study: 1463155

Group type: EXPERIMENTAL
Intervention: Enoximone 1.25 mg/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study: 3882290

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29557401

Group type: EXPERIMENTAL
Intervention: Immediate loading (within 48 h)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Early loading (at 6 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional loading (at 3 months)
Number of subjects: 54
Study: 26100763

Group type: EXPERIMENTAL
Intervention: Uterine closure technique with suture pulled in caudal direction (Group 1)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Uterine closure technique with suture pulled in cephalic direction (Group 2)
Number of subjects: 765
Study: 26174905

Group type: EXPERIMENTAL
Intervention: Donor screening for anti-A isoagglutinins
Number of subjects: 705
Study: 23945905

Group type: EXPERIMENTAL
Intervention: Depression (assessed using the 9-item Patient Health Questionnaire, scores ≥10)
Number of subjects: 2977
Study: 21918214

Group type: EXPERIMENTAL
Intervention: Familiarity with snack foods
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Expected satiation
Number of subjects: 70
Study: 19108662

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at varying doses (placebo, 0.15 mg/kg t.i.d., 0.3 mg/kg t.i.d., and 0.6 mg/kg t.i.d.) combined with behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (non-SMD subjects).
Number of subjects: 101
Study: 16298238

Group type: EXPERIMENTAL
Intervention: Brain magnetic activity recorded during a memory task using magnetoencephalography.
Number of subjects: 15
Study: 14622664

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate delivery system
Number of subjects: 149